Patent ID: 7744884

Claim:
A method of alleviating a symptom of a pathology associated with TLR4 activation, the method comprising administering an isolated antibody that binds a human Toll-like receptor 4 (TLR4)/human MD-2 complex to a subject in which such alleviation is desired in an amount sufficient to alleviate the symptom of the pathology in the subject, wherein the antibody comprises a heavy chain with three complementarity determining regions (CDRs) comprising a CDR1 region comprising an amino acid sequence comprising GGYSWH (SEQ ID NO:23); a CDR2 region comprising an amino acid sequence comprising YIHYSGYTDFNPSLKT (SEQ ID NO:24); and a CDR3 region comprising an amino acid sequence comprising KDPSDGFPY (SEQ ID NO:25); and a light chain with three CDRs comprising a CDR1 region comprising an amino acid sequence comprising RASQSISDHLH (SEQ ID NO:28); a CDR2 region comprising an amino acid sequence comprising YASHAIS (SEQ ID NO:29); and a CDR3 region comprising an amino acid sequence comprising QNGHSFPLT (SEQ ID NO:30); and wherein the antibody inhibits at least 50% of lipopolysaccharide (LPS)-induced IL-8 production in a solution comprising human TLR4/MD-2 transfected HEK293 cells when said antibody is added to said solution at a concentration of 10 μg/ml, as compared to the level of LPS-induced IL-8 production in the absence of said antibody.